The transition of rapamycin (sirolimus) from a soil-dwelling byproduct of Easter Island to the center of the longevity drug ethical debate represents a paradigm shift in preventive medicine. While this macrolide remains the only pharmacological intervention proven to extend lifespan across nearly all model organisms, its increasing off-label adoption by healthy "biohackers" has ignited a…

Cardiovascular disease remains the leading cause of mortality worldwide, with aging serving as the primary risk factor. As we age, the heart and blood vessels undergo progressive changes—including increased arterial stiffness, impaired relaxation (diastolic dysfunction), and a decline in endothelial health—often long before clinical symptoms appear. Rapamycin, an FDA-approved compound originally used in organ transplantation,…

Rapamycin is the strongest drug candidate in longevity research so far, but it is not yet a proven “true anti-aging drug” in humans. The evidence is compelling in animals and promising in early human studies, yet we still lack the kind of large, long-term trials needed to say it reliably slows human aging. Rapamycin sits…

Instead of watching our canine companions succumb to the inevitable decline of age-related disease, the rapidly advancing field of canine geroscience is proactively targeting the biological roots of aging. At the forefront of this movement is a highly targeted pharmacological intervention: using rapamycin to selectively inhibit the mechanistic target of rapamycin (mTOR) pathway. By dialing…

Recent studies show rapamycin extends lifespan in animals comparably to dietary restriction like intermittent fasting, but human data remains limited with both offering mTOR inhibition benefits. No clear winner emerges yet—rapamycin may edge out in late-life starts, while fasting proves more accessible. This post dives into mechanisms, trials, and real-world insights to help you weigh…

Rapamycin shows promise in slowing or partially reversing epigenetic clocks in preclinical models like human skin cells and mice, however human clinical evidence remains limited and mixed. Experts like Matt Kaeberlein highlight ongoing dog trials as key tests for translation, while users report variable biomarker shifts alongside side effects. This post dives into mechanisms, data,…

The quest to slow biological time is no longer fringe science; it's a multi-billion dollar industry. Walking into a pharmacy or scrolling online presents a dizzying array of pills and powders claiming to extend healthspan. But when you strip away the marketing, the question remains: What are the best longevity supplements actually supported by clinical data? While…

The search for Rapamycin capsules formulated for longevity has moved from fringe biohacking forums to mainstream medical consultations. Following the release of the PEARL trial results in 2025 and new data on DNA damage protection in early 2026, demand has surged. However, sourcing remains complex. Unlike over-the-counter supplements, rapamycin (sirolimus) is a prescription drug, and the formulation…

In 2026, the discussion around longevity has moved from "What is the best pill?" to "How do we balance the pathways?" The debate over Rapamycin vs. Metformin for longevity has reached a turning point in 2026. While both molecules dominated early geroscience discussions, recent meta-analyses and clinical data now distinguish between "fringe benefits" and "fundamental…

For many in the longevity community, the six-month mark is the "Gold Standard" milestone. It is the point where the initial placebo effects fade, and the real biological data—from lipid panels to biological age clocks—begins to tell a definitive story. While clinical trials like the ERAP trial for Alzheimer’s and the Kraig et al. study…